Skip to main content
SpringerLink
Log in

Testicular Cancer

Screening, Diagnostic and Therapeutic Considerations

  • Review Article
  • Diagnosis
  • Published:
Disease Management and Health Outcomes

Abstract

The treatment of germ-cell tumours of the testis can be considered as a model for cancer management, representing public education, diagnosis and cure with long term follow-up. Psychosocial distress, fertility and secondary tumour induction can also be studied. The aetiology of this disease is largely unknown; however, there is an increasing incidence in several regions such as Scandinavia, the UK and the US. Thus, the institution of preventive measures is needed.

At present, large scale screening of at-risk age groups is not justified because of the very low incidence of the disorder and lack of adequate screening tools.

Better education regarding the signs and symptoms of testicular cancer at schools and universities, perhaps including testicular self-examination and close follow-up of particular risk groups (those with maldescended testes or orchidopexy) may need more attention.

The management of the disease following orchiectomy and staging, both in the adjuvant setting and of patients with metastatic disease, has proved successful with cure rates ranging from 85 to 98% for the majority of patients. The introduction of cisplatin-containing combination chemotherapy, careful surveillance and improved diagnostic tools have contributed to the successful treatment of testicular cancer. A small subgroup of patients with poor prognosis (50% cure rate) still need more intensive therapy.

Treatment is successful for most patients and more time can be spent reducing acute and late toxicity in long term survivors and studying sociopsychological aspects in these men. Eventually, it may not be necessary for further randomised trials in patients with good prognosis because only minor improvements are being obtained from great efforts and costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Devesa SS, Blot WJ, Stone BJ, et al. Recent cancer trends in the United States. J Natl Cancer Inst 1995; 87(3): 175–82.

    Article  PubMed  CAS  Google Scholar 

  2. Brown LM, Pottern LM, Hoover RN, et al. Testicular cancer in the United States: trends in incidence and mortality. Int J Epidemiol 1986; 15(2): 164–70.

    Article  PubMed  CAS  Google Scholar 

  3. Stone JM, Cruickshank DG, Sandeman TF, et al. Trebling of the incidence of testicular cancer in victoria, Australia (1950–1985). Cancer 1991; 68(1): 211–9.

    Article  PubMed  CAS  Google Scholar 

  4. Møller H. Trends in sex-ratio, testicular cancer and male reproductive hazards: are they connected? APMIS 1998; 106: 232–8.

    Article  PubMed  Google Scholar 

  5. Einhorn LH, Richie JP, Schipley WU, et al. editors. 4th ed. Cancer of the testis. Philadelphia: Lippincott, 1993: 1126–51.

    Google Scholar 

  6. Spitz MR, Sider JG, Pollack ES, et al. Incidence and descriptive features of testicular cancer among United States whites, blacks, and hispanics, 1973–1982. Cancer 1986; 58(8): 1785–90.

    Article  PubMed  CAS  Google Scholar 

  7. Swerdlow AJ. New research in testicular cancer epidemiology. In: Jones WG, Appleyard J, Harnden P, et al., editors. Germ Cell Tumours IV. London: John Libbey, 1997: 3–8.

    Google Scholar 

  8. Grove JS. The cryptorchid problem (LeComete (1851) quoted). J Urol 1954; 71: 735.

    PubMed  CAS  Google Scholar 

  9. Austoker J. Screening for ovarian, prostatic, and testicular cancers. BMJ 1994; 309(6950): 315–20.

    Article  PubMed  CAS  Google Scholar 

  10. Swerdlow AJ, Huttly SR, Smith PG. Testicular cancer and antecedent diseases. Br J Cancer 1987; 55(1): 97–103.

    Article  PubMed  CAS  Google Scholar 

  11. United Kingdom Testicular Cancer Study Group. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. BMJ 1994; 308: 1393–9.

    Article  Google Scholar 

  12. Farrer JH, Walker AH, Rajfer J. Management of the postpubertal cryptorchid testis: a statistical review. J Urol 1985; 134(6): 1071–6.

    PubMed  CAS  Google Scholar 

  13. Pottern LM, Brown LM, Hoover RN, et al. Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. J Natl Cancer Inst 1985; 74(2): 377–81.

    PubMed  CAS  Google Scholar 

  14. Abratt R P, Reddi VB, Sarembock LA. Testicular cancer and cryptorchidism. Br J Urol 1992; 70(6): 656–9.

    Article  PubMed  CAS  Google Scholar 

  15. Jones BJ, Thornhill JA, O’Donnell B, et al. Influence of prior orchiopexy on stage and prognosis of testicular cancer. Eur Urol 1991; 19(3): 201–3.

    PubMed  CAS  Google Scholar 

  16. Strader CH, Weiss NS, Daling JR, et al. Cryptorchism, or-chiopexy, and the risk of testicular cancer. Am J Epidemiol 1988; 127(5): 1013–8.

    PubMed  CAS  Google Scholar 

  17. Prener A, Engholm G, Jensen OM. Genital anomalies and risk for testicular cancer in Danish men. Epidemiology 1996; 7(1): 14–9.

    Article  PubMed  CAS  Google Scholar 

  18. Pinczowski D, McLaughlin JK, Lackgren G, et al. Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia. J Urol 1991; 146(5): 1291–4.

    PubMed  CAS  Google Scholar 

  19. Pike MC, Chilvers C, Peckham MJ. Effect of age at orchidopexy on risk of testicular cancer. Lancet 1986; I(8492): 1246–8.

    Article  Google Scholar 

  20. Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993; 341(8857): 1392–5.

    Article  PubMed  CAS  Google Scholar 

  21. Pryor J P, Cameron KM, Chilton C P, et al. Carcinoma in situ in testicular biopsies from men presenting with infertility. Br J Urol 1983; 55(6): 780–4.

    Article  PubMed  CAS  Google Scholar 

  22. Auger J, Kunstmann JM, Czyglik F, et al. Decline in semen quality among fertile men in Paris during the past 20 years. N Engl J Med 1995; 332(5): 281–5.

    Article  PubMed  CAS  Google Scholar 

  23. Skakkebaek NE. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology 1978; 2(3): 157–70.

    Article  PubMed  CAS  Google Scholar 

  24. Marshall FF. Anomalies associated with cryptorchidism. Urol Clin North Am 1982; 9(3): 339–47.

    PubMed  CAS  Google Scholar 

  25. Gallagher R P, Huchcroft S, Phillips N, et al. Physical activity, medical history, and risk of testicular cancer (Alberta and British Columbia, Canada). Cancer Causes Control 1995; 6(5): 398–406.

    Article  PubMed  CAS  Google Scholar 

  26. Thonneau P, Ducot B, Bujan L, et al. Heat exposure as a hazard to male fertility [letter]. Lancet 1996; 347(8995): 204–5.

    Article  PubMed  CAS  Google Scholar 

  27. Figa-Tatamanca I, Cini C, Varricchio GC, et al. Effects of prolonged autovehicle driving on male reproductive function: a study among taxi drivers. Am J Ind Med 1996; 30: 750–8.

    Article  Google Scholar 

  28. Micusset R, Bujan L, Mieusset R, et al. Testicular heating and possible contributions to male infertility: a review. Int J Androl 1995; 18: 169–84.

    Article  Google Scholar 

  29. Harland SJ, Nicholson PW. Implications of a hereditary model for testis cancer. In: Jones WG, Appleyard J, Harnden P, et al., editors. Germ cell tumours IV. London: John Libbey, 1997: 17–25.

    Google Scholar 

  30. Dieckman KP, Loy V. Prevalence of contralateral testicular in-traepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996; 14(12): 3126–31.

    Google Scholar 

  31. Parkinson MC, Swerdlow AJ, Pike MC. Carcinoma in situ in boys with cryptorchidism: when can it be detected? Br J Urol 1994; 73(4): 431–5.

    Article  PubMed  CAS  Google Scholar 

  32. Muller J. Abnormal infantile germ cells in development of carcinoma in situ in maldeveloped testes. Oxford: Blackwell Scientific Publication, 1987.

    Google Scholar 

  33. Swerdlow AJ, Higgins CD, Pike MC. Risk of testicular cancer in cohort of boys with cryptorchidism. BMJ 1997; 314(7093): 1507–11.

    Article  PubMed  CAS  Google Scholar 

  34. Berger C P, Lycklama NA. Epididymitis or testis malignancy? [in Dutch]. Ned Tijdschr Geneeskd 1996; 140(33): 1669–71.

    PubMed  CAS  Google Scholar 

  35. Iammarino NK, Scardino PT. Testicular cancer: the role of the primary care physician in prevention and early detection. Tex Med 1991; 87(5): 66–71.

    PubMed  CAS  Google Scholar 

  36. Willson P. Testicular, prostate and penile cancers in primary care settings: the importance of early detection. Nurse Pract 1991; 16(11): 18–20.

    Article  PubMed  CAS  Google Scholar 

  37. Richie J P, Birnholz J, Garnick MB. Ultrasonography as a diagnostic adjunct for the evaluation of masses in the scrotum. Surg Gynecol Obstet 1982; 154(5): 695–8.

    PubMed  CAS  Google Scholar 

  38. Bajorin DF, Bosl GJ. The use of serum tumor markers in the prognosis and treatment of germ cell tumors. Princ Pract Oncol 1992; 6(1): 1–10.

    Google Scholar 

  39. Peckham MJ, McElwain TJ, Barrett A, et al. Combined management of malignant teratoma of the testis. Lancet 1979; 267–70.

    Google Scholar 

  40. Bosl GJ, Bajorin DF, Sheinfeld J, et al. Cancer: priciples and practice of oncology. 5th ed. Philadelphia: JB Lippincott, 1997: 1397–425.

    Google Scholar 

  41. Devita VT, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: JB Lippincott, 1997; 128: 2186–92.

    Google Scholar 

  42. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242–53.

    Article  PubMed  CAS  Google Scholar 

  43. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10: 1762–8.

    PubMed  CAS  Google Scholar 

  44. Peckham MJ, Barrett A, Husband JE, et al. Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet 1982; 11: 678–80.

    Article  Google Scholar 

  45. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council Report. J Clin Oncol 1996: 14: 1106–13.

    PubMed  CAS  Google Scholar 

  46. Monynihan C. Testicular cancer: the psychosocial problems of patients and their relatives. Cancer Surv 1987; 6: 477–510.

    Google Scholar 

  47. Cullen M, James N. Adjuvant therapy for stage I testicular cancer. Tumour review. Cancer Treat Rev 1996; 22: 253–64.

    Article  PubMed  CAS  Google Scholar 

  48. Donohue JP, Thornhill JA, Foster RS, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965–1989): modifications of technique and impact on ejaculation. J Urol 1993; 149: 237–43.

    PubMed  CAS  Google Scholar 

  49. Skinner DG, Melamud A, Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymphnode dissection. J Urol 1982; 127: 1107–10.

    PubMed  CAS  Google Scholar 

  50. Baniel J, Roth BJ, Foster RS, et al. Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. Ann Surg Oncol 1996; 3: 86–93.

    Article  PubMed  CAS  Google Scholar 

  51. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995: 13: 1188–94.

    PubMed  CAS  Google Scholar 

  52. Fosså SD, Nesland JM, Wæhre H, et al. DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 1991; 67: 1874–7.

    Article  PubMed  Google Scholar 

  53. Sesterhenn IA, Weiss RB, Mostofi FK, et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 1992; 10: 69–78.

    PubMed  CAS  Google Scholar 

  54. Leibovitch I, Foster RS, Kopecky KK, et al. Identification of clinical stage a nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic and radiologic assessment. J Clin Oncol 1998; 16: 261–8.

    PubMed  CAS  Google Scholar 

  55. Steyerberg EW, Keizer HJ, Fossa SD, et al. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. Br J Cancer 1996; 74(9): 1492–8.

    Article  PubMed  CAS  Google Scholar 

  56. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13(5): 1177–87.

    PubMed  CAS  Google Scholar 

  57. Steyerberg EW, Keizer HJ, Fossa SD, et al. Validity of Predictions of residual retroperitoneal mass histology in non-seminomatous testicular cancer. J Clin Oncol 1998; 16(1): 269–74.

    PubMed  CAS  Google Scholar 

  58. Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14: 1637–41.

    PubMed  CAS  Google Scholar 

  59. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997; 33: 1234–41.

    Article  PubMed  CAS  Google Scholar 

  60. Stiller CA. Non-specialist units, clinical trials and survival from testicular cancer. Eur J Cancer 1995; 31A: 289–91.

    Article  PubMed  CAS  Google Scholar 

  61. Stiller CA. Centralised treatment entry to trials and survival. Br J Cancer 1994; 70: 352–62.

    Article  PubMed  CAS  Google Scholar 

  62. Oliver RTD. Rare cancers and specialist centres. BMJ 1986; 292: 641–2.

    Article  PubMed  CAS  Google Scholar 

  63. Thornhill JA, Walsh A, Conroy RM, et al. Physician dependent prognostic variables in the management of testicular cancer. Br J Urol 1988; 62: 244–9.

    Article  Google Scholar 

  64. Harding MJ, Paul J, Gillis CR, et al. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 1993; 341: 999–1002.

    Article  PubMed  CAS  Google Scholar 

  65. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with non-seminomatous metastatic testicular cancer. J Clin Oncol 1991; 9: 818–26.

    PubMed  CAS  Google Scholar 

  66. Mead GM, Stenning SP, Parkinson MC, et al. The second medical research Counsil Study of prognostic factors in non-semi-nomatous germ cell tumours. J Clin Oncol 1992; 10: 85–94.

    PubMed  CAS  Google Scholar 

  67. Collette L, Sylvester RJ, Stenning S P, et al. Does the treating institution have an impact on the overall and failure-free survival of patients with “poor prognosis” metastatic non-semi-nomatous germ cell tumours? In: Jones WG, Appleyard J, Harnden P, et al., editors. Germ cell tumours IV. London: John Libbey, 1997: 367–8.

    Google Scholar 

  68. Germa-Lluch JR, Begent RH, Bagshawe KD. Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer 1980; 42(6): 850–5.

    Article  PubMed  CAS  Google Scholar 

  69. Stoter G, Bosl GJ, Droz JP. Prostate cancer and testicular cancer. Prognostic factors in metastatic germ cell tumours. EORTC genitourinary group monograph. New York: Wiley-Liss, 1990: 313–9.

    Google Scholar 

  70. Stoter G, Sylvester R, Sleijfer DT, et al. Multivariate analysis of prognostic factors in patients with disseminated non-seminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res 1989; 47(19): 2714–8.

    Google Scholar 

  71. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594–603.

    Google Scholar 

  72. Price P, Hogan SJ, Bliss JM, et al. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time II. Prognostic significance in patients treated by chemotherapy [published erratum appears in Eur J Cancer 1990; 26 (8): 925]]. Eur J Cancer 1990; 26(4): 453–7.

    Article  PubMed  CAS  Google Scholar 

  73. Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43(7): 3403–7.

    PubMed  CAS  Google Scholar 

  74. Wilson J, Jungner G. Priciples and practice of screening for disease. WHO Public Health Paper 1968; 34.

    Google Scholar 

  75. American Cancer Society. Guidelines for the cancer-related check-up: recommendations and rationale. New York: American Cancer Society, 1980.

    Google Scholar 

  76. National Cancer Institute. Working guidelines for early cancer detection: rationale and supporting evidence to decrease mortality. Bethesda (MD): National Cancer Institute, 1987.

    Google Scholar 

  77. Sladden M, Dickinson J. Testicular cancer. How effective is screening? Aust Fam Physician 1993; 22(8): 1350–6.

    PubMed  CAS  Google Scholar 

  78. Paul AB, Ladds TJ, Payne SR. Testicular self-examination: can the primary care diagnosis of testicular masses be improved? In: Jones WG, Appleyard J, Harnden P, et al., editors. Germ cell tumours IV. London: John Libbey, 1997: 383–7.

    Google Scholar 

  79. Conklin M, Klint K, Morway A, et al. Should health teaching include self-examination of the testes? Am J Nurs 1978; 78(12): 2073–4.

    PubMed  CAS  Google Scholar 

  80. Garnick MB, Mayer RJ, Richie J P. Testicular self-examination [letter]. N Engl J Med 1980; 302: 297.

    Article  PubMed  CAS  Google Scholar 

  81. Bosl GJ, Vogelzang NJ, Goldman A, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981; II(8253): 970–3.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, K1-P, Leiden University Medical Centre, P.O. Box 9600, 2300, RC Leiden, The Netherlands

    Daan ten Bokkel Huinink &  Hendrik Jan Keizer

Authors
  1. Daan ten Bokkel Huinink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hendrik Jan Keizer
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

About the Authors: Hendrik Jan Keizer, MD, PhD, is Associate Professor of Clinical Oncology. His main interests are germ cell tumours, cancer of the gastrointestinal tract and anticancer drug pharmacology.

Daan ten Bokkel Huinink, MD, is a board certified Medical Oncologist. His main interests are cancer of the head and neck, cancer of the gastrointestinal tract and research on immunotherapy of breast cancer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

ten Bokkel Huinink, D., Keizer, H.J. Testicular Cancer. Dis-Manage-Health-Outcomes 4, 57–72 (1998). https://doi.org/10.2165/00115677-199804020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-199804020-00001

Keywords

Search

Navigation